Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Biosimilar Guidance Offers Window To Bypass Comparative Trials

Executive Summary

Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8

You may also be interested in...



Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity

An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea

Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity

An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea

Lovenox Generics Might Be Slowed In U.S. Because Of EU Guidance, Sanofi Hopes

Sanofi-Aventis says an emerging European guideline prescribing clinical trials for low molecular weight heparin generics could sway FDA as it considers copies of its clot-busting blockbuster Lovenox

Related Content

UsernamePublicRestriction

Register

PS046956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel